Flawed, scandalous trials tank FDA expert support for MDMA therapy

Enlarge / MDMA pills up close.Getty | Universal History Archive

After a remarkably sensational regulatory drug review, advisers for the Food and Drug Administration on Tuesday voted overwhelmingly against approving midomafetamine (MDMA, aka ecstasy or molly) as part of therapy for post-traumatic stress disorder.

In a response to the question, “Do the available data show that the drug is effective in patients with posttraumatic stress disorder?” advisers voted 9 “no” to 2 “yes” against MDMA. In response to the second question, “Do the benefits of midomafetamine with FDA’s proposed risk

→ Continue reading at Ars Technica

Related articles

Comments

Share article

Latest articles